Clinical Trial Protocol
Iranian Registry of Clinical Trials

03 Jun 2026

Effect of Celecoxib in the prevention of pancreatitis after Endoscopic retrograde cholangiopancreatography (ERCP)

Protocol summary

Summary

Acute pancreatitis is the most common and most feared complication during Endoscopic retrograde cholangiopancreatography (ERCP) and it has high prevalance of mortality and morbidity rarely. one risk factor for this complication is canulation in pancreatobilliary duct during ERCP. Observed that the use of medications such as nonsteroidal anti-inflammatory drugs may prevent this complication. This study is a placebo-controlled clinical trial with simple sampling. Persons between 15 to 55 years without advanced systemic disease and were not drug addicts or continuous drug use and with mild hepatobilliary disease without fibrosis or cirrhosis are enrolled. If patient has no desire to continue study or in other complications after ERCP are excluded. Two groups of 38 patients enrolled in the drug group that use Celecoxib capsule 3 capsule 100mg and the placebo group that use 3 capsule 100mg placebo capsule manufacturing pharmaceutical Sajad, 5 hours before the intervention. serum amylase level is measured at capsule use time and 2 hours after intervention and patient is evaluate about pancreatitis signs and symptoms until 2 hours after intervention.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201207252417N8**
Registration date: **2012-08-06, 1391/05/16**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

Registration date

2012-08-06, 1391/05/16

Registrant information

Name

Firouzeh Moeinzadeh

Name of organization / entity

Isfahan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 1625 5555

Email address

moinzade@resident.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research, Isfahan University of Medical Sciences

Expected recruitment start date

2012-04-20, 1391/02/01

Expected recruitment end date

2012-08-21, 1391/05/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Celecoxib in the prevention of pancreatitis after Endoscopic retrograde cholangiopancreatography (ERCP)

Public title

Effect of Celecoxib in the prevention of pancreatitis after Endoscopic retrograde cholangiopancreatography (ERCP)

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: 1- no advanced systemic disease 2- no addiction 3- no continouse drug use 4- mild hepatobilliary disease with liver enzyme elevation to 4 times of normal upper limit. 5- without fibrosis, cirrhosis

or infectious hepatitis exclusion criteria: 1- other side effects except pancreatitis after ERCP 2- Lack of consent to cooperate in trial.

Age
From **15 years** old to **55 years** old

Gender
Both

Phase
N/A

Groups that have been masked
No information

Sample size
Target sample size: **76**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Triple blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Vice Chancellor for Research, Isfahan University of Medical Sciences

Street address
Hezar Jarib street

City
Isfahan

Postal code

Approval date
2011-11-09, 1390/08/18

Ethics committee reference number
390375

Health conditions studied

1

Description of health condition studied
Acute Pancreatitis

ICD-10 code
K85.8

ICD-10 code description
Other acute pancreatitis

Primary outcomes

1

Description
Pancreatitis

Timepoint
Befor and 2 hours after Endoscopic retrograde cholangiopancreatography

Method of measurement
Pain and clinical signs

2

Description
Serum amylase level

Timepoint
Befor and 2 hours after Endoscopic retrograde cholangiopancreatography

Method of measurement
ELISA kits: International Unit per Littre

Secondary outcomes

empty

Intervention groups

1

Description
Cap celecoxib 100mg, 3 capsuls. Sajjad Pharmaceutical Company, Mashad. 5 hours before Endoscopic retrograde cholangiopancreatography

Category
Treatment - Drugs

2

Description
Cap Placebo, 3 capsuls. Sajjad Pharmaceutical Company, Mashad. 5 hours before Endoscopic retrograde cholangiopancreatography

Category
Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center
Alzahra hospital, Endoscopy Department

Full name of responsible person
Dr. Zhaleh Derakhshan

Street address
Alzahra Hospital

City
Isfahan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Vice Chancellor for Research, Isfahan University of Medical Sciences

Full name of responsible person
Dr. Peyman Adibi

Street address
Hezar Jarib Street.Isfahan University of Medical Sciences

City
Isfahan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Vice Chancellor for Research, Isfahan University of Medical Sciences

Proportion provided by this source
100

Public or private sector
empty

Domestic or foreign origin
empty

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
Isfahan University of Medical Science

Full name of responsible person
Dr zhaleh derakhshan

Position
Internal Medicine Resident

Other areas of specialty/work

Street address
Alzahra hospital

City
Isfahan

Postal code

Phone
+98 31 1668 5555

Fax

Email
mona.derakhshan@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Isfahan University of Medical Science

Full name of responsible person
Dr Mohammad Minakari

Position
Associate Professor of Gastroentrology

Other areas of specialty/work

Street address
Alzahra hospital, Gastroentrology ward.

City
Isfahan

Postal code

Phone
+98 31 1628 5555

Fax

Email
minakari@med.mui.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity
Isfahan University of Medical Sciences

Full name of responsible person
Dr Firouzeh Moeinzadeh

Position
Internist

Other areas of specialty/work

Street address
Alzahra Hospital

City
Isfahan

Postal code

Phone
+98 31 1668 5555

Fax

Email
moinzade@resident.mui.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty

Study Protocol
empty

Statistical Analysis Plan
empty

Informed Consent Form
empty

Clinical Study Report
empty

Analytic Code
empty

Data Dictionary
empty